Literature DB >> 31489579

MiR-148a inhibits the proliferation and migration of glioblastoma by targeting ITGA9.

Tong-Jiang Xu1, Peng Qiu1, Yu-Bao Zhang1, Sheng-Yuan Yu1, Guang-Ming Xu1, Wei Yang2.   

Abstract

Glioblastoma is a common malignant primary intracranial tumor characterized by rapid invasive growth and a high recurrence rate after surgery. MicroRNAs (miRNAs) are involved in cell proliferation, differentiation, and apoptosis, and abnormal miRNA expression is associated with the occurrence and progression of various tumors, including glioblastomas. The aim of this study was to determine the levels of miR-148a and integrin subunit alpha 9 (ITGA9) in glioblastoma tissues and cells and their involvement in cancer cell proliferation and migration. Glioblastoma tissues from 19 patients and two glioblastoma cell lines (U87 and LN229) were used in this study. The effects of miR-148a on cell viability, proliferation, colony formation, migration, and invasion were assessed. Glioblastomas were xenografted in nude mice to examine the effects of miR-148a overexpression on tumor growth in vivo. Levels of ITGA9 mRNA and protein in glioblastoma tissues were detected by quantitative reverse transcription PCR and western blot analysis, respectively. The interaction between miR-148a and ITGA9 was determined by a dual-luciferase reporter gene assay. We found that the overexpression of miR-148a decreases the proliferation, clustering, migration, and invasiveness of U87 and LN229 cells and inhibits the tumorigenicity of xenografted glioblastomas. We confirmed that ITGA9 is the target of miR-148a. Restoration of ITGA9 expression reversed the decreased viability, migration, and invasiveness of glioblastoma cells induced by miR-148a overexpression. Our findings indicate that miR-148a can suppress the malignant phenotype of glioblastoma by targeting ITGA9 and identify ITGA9 as a potential therapeutic target for glioblastoma.

Entities:  

Keywords:  Glioblastoma; ITGA9; Malignant; Migration; Proliferation; miR-148a

Mesh:

Substances:

Year:  2019        PMID: 31489579     DOI: 10.1007/s13577-019-00279-9

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  29 in total

1.  Activation-enhanced alpha(IIb)beta(3)-integrin-cytoskeleton interactions outside of focal contacts require the alpha-subunit.

Authors:  D F Kucik; T E O'Toole; A Zheleznyak; D K Busettini; E J Brown
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

2.  Cell Adhesion Mediated by VCAM-ITGα9 Interactions Enables Lymphatic Development.

Authors:  Yiqing Yang; David Enis; Hui Zheng; Stephanie Chia; Jisheng Yang; Mei Chen; Veerpal Dhillon; Thalia Papayannapoulou; Mark L Kahn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-05       Impact factor: 8.311

Review 3.  Integrins in cancer: biological implications and therapeutic opportunities.

Authors:  Jay S Desgrosellier; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

Review 4.  Metastasis suppressors in breast cancers: mechanistic insights and clinical potential.

Authors:  Christopher R Bohl; Sitaram Harihar; Warren L Denning; Rahul Sharma; Danny R Welch
Journal:  J Mol Med (Berl)       Date:  2013-12-06       Impact factor: 4.599

5.  Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors.

Authors:  Luydmila A Mostovich; Tatiana Y Prudnikova; Aleksandr G Kondratov; Dina Loginova; Pavel V Vavilov; Valentina I Rykova; Sergei V Sidorov; Tatiana V Pavlova; Vladimir I Kashuba; Eugene R Zabarovsky; Elvira V Grigorieva
Journal:  Cell Adh Migr       Date:  2011 Sep-Oct       Impact factor: 3.405

6.  Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.

Authors:  Josie Hayes; Helene Thygesen; Charlotte Tumilson; Alastair Droop; Marjorie Boissinot; Thomas A Hughes; David Westhead; Jane E Alder; Lisa Shaw; Susan C Short; Sean E Lawler
Journal:  Mol Oncol       Date:  2014-11-28       Impact factor: 6.603

Review 7.  MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled.

Authors:  Catherine M Greene; Robert B Varley; Matthew W Lawless
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 8.  MicroRNAs as potential biomarkers in human solid tumors.

Authors:  Jun Shen; Sanford A Stass; Feng Jiang
Journal:  Cancer Lett       Date:  2012-11-27       Impact factor: 8.679

9.  Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis.

Authors:  Eleni Bazigou; Sherry Xie; Chun Chen; Anne Weston; Naoyuki Miura; Lydia Sorokin; Ralf Adams; Andrés F Muro; Dean Sheppard; Taija Makinen
Journal:  Dev Cell       Date:  2009-08       Impact factor: 12.270

10.  MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis.

Authors:  Naoya Sakamoto; Yutaka Naito; Naohide Oue; Kazuhiro Sentani; Naohiro Uraoka; Htoo Zarni Oo; Kazuyoshi Yanagihara; Kazuhiko Aoyagi; Hiroki Sasaki; Wataru Yasui
Journal:  Cancer Sci       Date:  2014-01-06       Impact factor: 6.716

View more
  11 in total

1.  MiR-382 Functions on the Regulation of Melanogenesis via Targeting dct in Rainbow Trout (Oncorhynchus mykiss).

Authors:  Shenji Wu; Jinqiang Huang; Yongjuan Li; Zhe Liu; Lu Zhao
Journal:  Mar Biotechnol (NY)       Date:  2022-07-27       Impact factor: 3.727

2.  Circular RNA circ_0079593 facilitates glioma development via modulating miR-324-5p/XBP1 axis.

Authors:  Pengcheng Wang; Tong Wang; Lei Dong; Zhenkuan Xu; Shouzhong Guo; Chengyue Chang
Journal:  Metab Brain Dis       Date:  2022-07-06       Impact factor: 3.655

3.  Circ_0001982 Up-regulates the Expression of E2F1 by Adsorbing miR-1205 to Facilitate the Progression of Glioma.

Authors:  Zhihui Ma; Jinyang Ma; Bojuan Lang; Fei Xu; Bo Zhang; Xiangyu Wang
Journal:  Mol Biotechnol       Date:  2022-08-22       Impact factor: 2.860

4.  miR-218 affects the ECM composition and cell biomechanical properties of glioblastoma cells.

Authors:  Małgorzata Grabowska; Konrad Kuczyński; Monika Piwecka; Alicja Rabiasz; Joanna Zemła; Paweł Głodowicz; Dariusz Wawrzyniak; Małgorzata Lekka; Katarzyna Rolle
Journal:  J Cell Mol Med       Date:  2022-06-15       Impact factor: 5.295

5.  MicroRNA-6071 Suppresses Glioblastoma Progression Through the Inhibition of PI3K/AKT/mTOR Pathway by Binding to ULBP2.

Authors:  Yunyan Zhou; Hongwei An; Gang Wu
Journal:  Onco Targets Ther       Date:  2020-09-23       Impact factor: 4.147

6.  Overexpression of microRNA-129-5p in glioblastoma inhibits cell proliferation, migration, and colony-forming ability by targeting ZFP36L1.

Authors:  Xu Guo; Haozhe Piao; Ye Zhang; Peixin Sun; Bing Yao
Journal:  Bosn J Basic Med Sci       Date:  2020-11-02       Impact factor: 3.363

7.  MicroRNA‑199a‑5p suppresses cell proliferation, migration and invasion by targeting ITGA3 in colorectal cancer.

Authors:  Lijun Tian; Mingtong Chen; Qiang He; Qiuliang Yan; Chunbao Zhai
Journal:  Mol Med Rep       Date:  2020-07-10       Impact factor: 2.952

8.  The Status of EGFR Modulates the Effect of miRNA-200c on ZEB1 Expression and Cell Migration in Glioblastoma Cells.

Authors:  Lisandra Muñoz-Hidalgo; Teresa San-Miguel; Javier Megías; Eva Serna; Silvia Calabuig-Fariñas; Daniel Monleón; Rosario Gil-Benso; Miguel Cerdá-Nicolás; Concha López-Ginés
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 5.923

9.  Predicting Glioblastoma Cellular Motility from In Vivo MRI with a Radiomics Based Regression Model.

Authors:  Kellen Mulford; Mariah McMahon; Andrew M Gardeck; Matthew A Hunt; Clark C Chen; David J Odde; Christopher Wilke
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

10.  MicroRNA-148a Regulates the Proliferation and Differentiation of Ovine Preadipocytes by Targeting PTEN.

Authors:  Xiayang Jin; Zhiyun Hao; Mengli Zhao; Jiyuan Shen; Na Ke; Yize Song; Lirong Qiao; Yujie Lu; Liyan Hu; Xinmiao Wu; Jiqing Wang; Yuzhu Luo
Journal:  Animals (Basel)       Date:  2021-03-15       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.